Evidence map›Paper›PMID 32028264›Full record

ArticleAging2020

Identification of an immune-related risk signature for predicting prognosis in clear cell renal cell carcinoma.

Xiaoliang Hua, Juan Chen, Yang Su, Chaozhao Liang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Xiaoliang HuaDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Juan ChenThe Key Laboratory of Aquatic Biodiversity and Conservation of Chinese Academy of Sciences, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, China.
Yang SuDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Chaozhao LiangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
First Affiliated Hospital of Anhui Medical University · CNAnhui Medical University · CNUniversity of Chinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune status affects the initiation and progression of clear cell renal cell carcinoma (ccRCC), the most common subtype of renal cell carcinoma. In this study, we identified an immune-related, five-gene signature that improves survival prediction in ccRCC. Patients were classified as high- and low-risk based on the signature risk score. Survival analysis showed differential prognosis, while principal component analysis revealed distinctly different immune phenotypes between the two risk groups. High-risk patients tended to have advanced stage, higher grade disease, and poorer prognoses. Functional enrichment analysis showed that the signature genes were mainly involved in the cytokine-cytokine receptor interaction pathway. Moreover, we found that tumors from high-risk patients had higher relative abundance of T follicular helper cells, regulatory T cells, and M0 macrophages, and higher expression of PD-1, CTLA-4, LAG3, and CD47 than low-risk patients. This suggests our gene signature may not only serve as an indicator of tumor immune status, but may be a promising tool to select high-risk patients who may benefit from immune checkpoint inhibitor therapy. Multivariate Cox regression analysis showed that the signature remained an independent prognostic factor after adjusting for clinicopathological variables, while prognostic accuracy was further improved after integrating clinical parameters into the analysis.

Indexed as

AgedAntigens, CDCarcinoma, Renal CellCD47 AntigenChemokine CXCL5CTLA-4 AntigenCytokinesFemaleHumansInterferon Regulatory Factor-7Janus Kinase 3Kidney NeoplasmsLymphocyte Activation Gene 3 ProteinMacrophagesMaleMiddle AgedAntigens, CDCD47 AntigenCD47 protein, humanChemokine CXCL5CTLA-4 AntigenCTLA4 protein, humanCXCL5 protein, humanCytokinesInterferon Regulatory Factor-7IRF7 protein, humanJAK3 protein, humanJanus Kinase 3KDR protein, humanLag3 protein, humanLymphocyte Activation Gene 3 ProteinPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, CytokineSHC1 protein, humanSrc Homology 2 Domain-Containing, Transforming Protein 1Vascular Endothelial Growth Factor Receptor-2clear cell renal cell carcinomagene signatureimmune-related geneprognostic modeltumor immunology

Identifiers

PMID32028264
PMCPMC7041771
OpenAlexW3005141815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.